Oslo, Norway, 22 April 2026 – Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the publication of the Annual Report for 2025. The Board of Oncoinvent ASA has approved the annual accounts for 2025. The … Read more
Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results. Oncoinvent’s management team will give an online presentation to investors, analysts and the press at 09:30 CET … Read more
Bergen, Norway, 20 August 2025 – BerGenBio ASA (OSE: BGBIO today announced financial results for the first half 2025. Highlights, including post period: In February, following a preliminary analysis of response data, BerGenBio decided to close its lead clinical study, BGBC016, in bemcentinib in combination with standard of care therapy in first line … Read more
Bergen, Norway – 29 April 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2024 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2024 in pdf and … Read more
Bergen, Norway, August 21, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to … Read more
Bergen, Norway – 30 April 2024- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2023 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2023 in pdf and European … Read more
Bergen 25 August 2023: Reference is made to the publication of the Second quarter and first half 2023 Financial Report on the 23 of August at 07:00 CET. The Financial Report is updated to include the Board of Directors Responsibility statement and is attached to this announcement and on our website. AttachmentsPDF PDF
BERGEN, Norway, August 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and first half ended June 30, 2023, and provided a business update. A briefing by BerGenBio’s senior management team will take place … Read more
Bergen, Norway – 28 April 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2022 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2022 in pdf and European … Read more
– Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients – – Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 – – BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT – BERGEN, Norway, August 23, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.